K.J. Harrison & Partners’s Moderna MRNA Stock Holding History

K.J. Harrison & Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-15,660	Closed	-$1.86M	–	224
2024 Q2	$1.86M	Buy	+15,660	New	+$1.98M	0.31%	87
2023 Q1	–	Sell	-4,000	Closed	-$973K	–	262
2022 Q4	$973K	Buy	+4,000	New	+$654K	0.19%	129
2020 Q4	–	Sell	-12,000	Closed	-$850K	–	302
2020 Q3	$850K	Buy	+12,000	New	+$837K	0.18%	138

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

K.J. Harrison & Partners's MRNA Position: Q3 2024 in Review

K.J. Harrison & Partners sold out of Moderna (MRNA) in Q3 2024, closing a stake of 15,660 shares — an estimated $1.86M sold.

K.J. Harrison & Partners first reported a position in MRNA in Q3 2020 and held it in 3 quarters. The position peaked at $1.86M in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

K.J. Harrison & Partners reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
K.J. Harrison & Partners sold 15,660 Moderna shares in Q3 2024, an estimated $1.86M.
K.J. Harrison & Partners first reported a position in Moderna in Q3 2020 and held it in 3 quarters.
K.J. Harrison & Partners's Moderna position peaked at $1.86M in Q2 2024.
788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on K.J. Harrison & Partners's 13F filing for Q3 2024, filed 25 Oct 2024.